+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 42 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the long-term safety, tolerability, and effectiveness of ML-007C-MA in adults with schizophrenia. This open-label Phase 2 study includes participants who have recently completed a previous related study or new participants enrolling directly. The study focuses on adults aged 18 to 65 diagnosed with schizophrenia who may benefit from ongoing pharmacotherapy and can maintain outpatient care. Participants will receive ML-007C-MA dosed at 2103 mg twice daily for up to 52 weeks. This single-group study does not involve placebo and assesses the medications impact over the treatment period. The study allows for continuous monitoring and adjustment based on the participants response and tolerability. During the study, participants will be involved in regular assessments to monitor safety and tolerability from the initial dose through the entire treatment period. Evaluations include clinical interviews, physical exams, ECGs, and laboratory tests to track any adverse effects or changes in health status. Researchers will also gather information from a reliable informant to support assessments. The total participation duration can be up to one year.

Age: 18Years - 65YearsAll GendersPhase 2
45 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety and tolerability of intermittent use of elismetrep for treating acute migraine attacks. This Phase 3 study compares two doses of elismetrep, 10 mg and 20 mg, to understand their safety profiles over an average of one year. The study involves adult participants who have previously used elismetrep in an acute treatment trial and met compliance requirements. Participants are randomly assigned to receive either 10 mg or 20 mg of elismetrep taken orally during migraine attacks. The study uses a triple-masked design to ensure unbiased results. The treatment period spans approximately one year, during which safety and adverse events are closely monitored. This includes tracking any adverse events leading to discontinuation or serious adverse events related to the study drug. During the study, participants will complete electronic diaries to record migraine episodes and medication use. They will also attend scheduled visits to assess safety and tolerability, including monitoring for adverse events. The research team will measure the proportion of participants experiencing treatment-emergent adverse events and serious adverse events through study completion. Participants are expected to use a personal smartphone to maintain study diaries and comply with study procedures throughout the study duration.

Age: 18Years +All GendersPhase 3
113 locations
P

Actively Recruiting

Researchers are evaluating zelquistinel, a drug aimed at reducing symptoms of major depressive disorder in adults aged 18 to 64 years. This Phase 2 clinical trial compares the effects and safety of zelquistinel to a placebo in participants diagnosed with major depressive disorder. The study will focus on changes in depression severity and monitor any medical issues that arise during treatment. Participants will take one tablet of either zelquistinel or placebo once a week for six weeks. The trial includes a screening period of up to 28 days, followed by a 42-day treatment phase, and then a four-week follow-up period. During treatment, participants will visit the clinic weekly to receive their dose and have their depression symptoms assessed using the Hamilton Depression Rating Scale-17. Throughout the study, participants will have their depression severity regularly evaluated, along with monitoring for adverse events or side effects. The study lasts up to 98 days, including screening, treatment, and follow-up. Researchers will measure changes in depression scores from the beginning to the end of treatment and monitor overall safety during this time.

Age: 18Years - 64YearsAll GendersPhase 2
32 locations
E

Actively Recruiting

Researchers are investigating a new approach to improve rehabilitation outcomes for patients with ankle instability, particularly among those who have experienced ankle sprains. This trial compares standard physical therapy alone to physical therapy combined with training on a rocky, uneven terrain treadmill, aiming to better prepare patients for real-world challenges and reduce the risk of future ankle injuries. The study will include adults aged 18 to 49 who have chronic ankle instability or recent ankle sprains. Participants will be randomly assigned to one of two groups one receiving up to twelve sessions of progressive proprioceptive training on an uneven treadmill over about six weeks plus standard physical therapy, and the other receiving only standard physical therapy for the same period. The uneven treadmill activities may include varied walking speeds, inclines, head turning, vision challenges, multitasking, and load carrying, all adjusted by therapists based on individual tolerance and benefit. Both groups will be followed for 18 months to monitor progress and reinjury. Throughout the study, participants will undergo multiple assessments, including patient-reported outcome tools like the Cumberland Ankle Instability Tool and Foot and Ankle Ability Measure, as well as performance tests and biomechanical evaluations such as muscle activation and plantar pressure measurements. These evaluations will occur at baseline, during treatment, at discharge around six weeks, and at several follow-up points up to 18 months. Researchers will track ankle function, physical activity levels, pain, fear of movement, and reinjury rates to understand the effects of the interventions.

Age: 18Years - 49YearsAll GendersPhase Not Applicable
2 locations
E

Actively Recruiting

Researchers are evaluating the effects of a new drug called NTX-1472, a V1a receptor antagonist, in adults with Social Anxiety Disorder SAD. This Phase 2 clinical trial aims to determine how safe and well tolerated NTX-1472 is, and how effectively it treats adults living with SAD. The study compares NTX-1472 to a matching placebo to better understand its impact on this condition. Participants will take either NTX-1472 or a placebo capsule once daily for 8 weeks. The study involves two groups one receiving the experimental drug and the other receiving the placebo. Over 14 weeks, participants will visit the clinic six times for health checkups and various tests related to the treatment and their condition. During the study, participants will undergo multiple assessments including the Liebowitz Social Anxiety Scale LSAS, Hamilton Anxiety Rating Scale HAM-A, and other scales measuring anxiety, depression, stress, loneliness, sleep quality, and overall severity of symptoms. Researchers will monitor any treatment-emergent adverse events from the start until week 8. This detailed evaluation helps assess the drugs safety and effects while participants continue their involvement over the full 14-week period.

Age: 18Years - 65YearsAll GendersPhase 2
11 locations
E

Actively Recruiting

Researchers are studying chronic migraine, a condition causing moderate to severe headaches often on one side of the head, sometimes with nausea, vomiting, and sensitivity to light or sound. This trial evaluates how well the medicine atogepant works compared to a placebo in preventing chronic migraine in participants aged 12 to 17 years. The study also monitors adverse events to assess safety. Participants will be randomly assigned to receive either oral atogepant tablets or placebo once daily for 12 weeks. This double-blind study means neither the participants nor the doctors know who receives the medicine or placebo. Following the treatment, participants will be observed for an additional 4 weeks. During the study, participants will visit hospitals or clinics regularly for assessments. They will complete daily diaries, undergo medical evaluations, blood tests, side effect checks, and questionnaires. The main outcomes include tracking adverse events and changes in monthly migraine days, along with measures of headache days, medication use, and quality of life over approximately 16 weeks.

Age: 12Years - 17YearsAll GendersPhase 3
66 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the study drug Seltorexant compared with a placebo in adults and elderly participants with major depressive disorder MDD, a common mood disorder marked by persistent sadness and loss of interest. This Phase 3 study includes a double-blind treatment phase to measure improvement in depressive symptoms specifically in participants with moderate-to-severe insomnia symptoms. The study also aims to assess long-term safety and tolerability of Seltorexant in an open-label treatment phase. During the double-blind phase, participants will take either a Seltorexant tablet or a matching placebo once daily for 42 days. Those who qualify for the open-label phase will continue taking Seltorexant daily for up to 6 months. The study compares the two groups to understand how well Seltorexant works alone in treating MDD. Participants will undergo clinical assessments including depression rating scales, sleep disturbance questionnaires, and safety evaluations such as vital signs, laboratory tests, electrocardiograms, and suicidality ratings. Researchers will also monitor withdrawal symptoms and sexual functioning during the open-label phase. The total participation duration may extend over several months to evaluate both efficacy and long-term safety outcomes.

Age: 18Years - 74YearsAll GendersPhase 3
53 locations
S

Actively Recruiting

Researchers are evaluating the addition of Tersolisib LY4064809STX-478 to other anti-cancer drugs as a first treatment for adults with advanced hormone receptor-positive HR and human epidermal growth factor receptor 2-negative HER2- breast cancer that has a PIK3CA genetic mutation. The study aims to assess the effectiveness and safety of this combination in people whose cancer cannot be cured by surgery alone. Participants may continue in the study as long as the treatment is helping and side effects are manageable. Participants will be randomly assigned to one of three groups two different doses of Tersolisib combined with a CDK46 inhibitor and endocrine therapy ET, or a placebo combined with the same drugs. The CDK46 inhibitor and ET are given orally or intramuscularly depending on the drug chosen by the investigator. Treatments are administered orally or by injection as appropriate. The study includes a phase 2 dose optimization portion and a phase 3 randomized, double-blind, placebo-controlled portion. During the study, participants will undergo regular assessments including scans and tests to measure tumor response and progression. Researchers will monitor overall response rate, progression-free survival, and other health outcomes for up to 5 to 7 years. Safety and drug levels in the blood will also be tracked. Participants quality of life and physical function will be evaluated using questionnaires. The total time in the study depends on individual treatment response and side effects.

Age: 18Years +All GendersPhase 3
364 locations
E

Actively Recruiting

Bipolar disorder is a serious and chronic mood condition affecting both adults and pediatric populations in the United States. This research aims to evaluate the safety and effectiveness of Icalcaprant in treating adults diagnosed with bipolar I or II disorder, focusing on depressive episodes. The study is a phase 2, randomized, placebo-controlled trial enrolling about 195 adults across approximately 35 sites. Participants will be randomly assigned to one of three groups two different doses of oral Icalcaprant or a matching placebo. They will take the assigned oral capsules once daily for six weeks. After the treatment period, there will be a four-week safety follow-up to monitor participants health. During the study, participants will attend regular visits at hospitals or clinics for medical assessments, blood tests, side effect monitoring, and questionnaires. The main outcomes measured include changes in depression severity using the Montgomery-sberg Depression Rating Scale and monitoring adverse events throughout the treatment and follow-up periods. This study is sponsored by AbbVie and aims to better understand treatment options for bipolar depression.

Age: 18Years - 65YearsAll GendersPhase 2
33 locations
E

Actively Recruiting

This research aims to evaluate the safety and effectiveness of atogepant, a medication currently approved for adults, in treating episodic migraine in children aged 6 to 17 years. The study focuses on pediatric participants who experience moderate to severe migraines with symptoms such as throbbing head pain, nausea, and sensitivity to light and sound. Limited treatment options exist for this age group, so the trial investigates different doses of atogepant to address this need. Participants are divided into groups based on age and receive either a placebo or low or high doses of atogepant tablets once daily for 12 weeks. Children aged 6 to 11 first undergo an open-label pharmacokinetic substudy to determine the appropriate dose before the double-blind treatment period. After the initial 12 weeks, participants either have a follow-up visit 4 weeks after their last dose or can continue receiving atogepant for an additional 52 weeks in an extension study. Throughout the study, participants attend regular visits at hospitals or clinics for medical assessments, blood tests, and questionnaires to monitor the effects of treatment and check for side effects. The main outcomes measured include changes in monthly migraine days and safety through adverse event tracking. The study plans to enroll about 450 children worldwide, with comprehensive monitoring over the treatment and follow-up periods.

Age: 6Years - 17YearsAll GendersPhase 3
98 locations

1-10 of 42

1